LTR Pharma has locked in Strive Specialties as its exclusive US pharmacy fulfilment partner for ROXUS, marking a critical step towards commercial launch in the US erectile dysfunction market.
- Binding term sheet with Strive Specialties for exclusive US pharmacy fulfilment
- Access to multi-state 503A pharmacy platform supporting national distribution
- Two-year initial exclusivity term with auto-renewal
- Supports multi-channel US commercialisation including telehealth and provider networks
- Definitive agreements to be finalised within 30 to 60 days
Exclusive Pharmacy Fulfilment Deal Advances US Launch
LTR Pharma (ASX:LTP) has taken a significant leap towards commercialising ROXUS in the US by signing a binding term sheet with Strive Specialties Inc., securing exclusive pharmacy fulfilment rights. This agreement establishes the critical infrastructure needed to dispense ROXUS prescriptions nationwide through a multi-state 503A personalised medicine pharmacy platform.
ROXUS, LTR Pharma's rapid-acting intranasal erectile dysfunction treatment, targets the expansive US market with a delivery method that distinguishes it from traditional oral PDE5 inhibitors. The intranasal spray offers onset within 10 minutes, catering to the increasing demand for on-demand ED therapies.
Multi-Channel Distribution and Launch Readiness
The deal with Strive Pharmacy not only secures fulfilment but also expands patient access by integrating ROXUS into telehealth, healthcare provider, and pharmacy networks. Strive operates across five US states with licenses covering all 50 states, providing a robust foundation for national distribution.
Under the terms, Strive holds exclusive US 503A pharmacy rights for an initial two-year term starting from commercial launch, with annual auto-renewal unless terminated. The binding elements include exclusivity, confidentiality, and service-level provisions, while broader commercial terms are still subject to negotiation and must be finalised within 30 days, extendable by mutual agreement.
Reducing Launch Execution Risk
This arrangement represents a key milestone in LTR Pharma's US commercialisation strategy, reducing execution risk by securing an experienced pharmacy partner ahead of launch. Executive Chairman Lee Rodne emphasised the importance of this operational infrastructure in supporting their multi-channel approach and broader market access initiatives.
Strive Pharmacy President Michael Walker highlighted the alignment between ROXUS's innovative profile and Strive's focus on personalised medicine, signalling a collaborative effort to ensure launch readiness and patient access.
Next Steps and Market Implications
Definitive agreements are expected to be negotiated in good faith and executed within the next 30 to 60 days. Commercial launch remains contingent on completing technology transfer and pharmacy onboarding processes. This partnership complements LTR Pharma's recent US telehealth distribution deal with Shed Holdings, which targets at least 150,000 ROXUS prescriptions in the first year, reinforcing a coordinated multi-channel commercial push.
While the term sheet is a binding commitment on key provisions, the final commercial terms and launch timing retain some uncertainty. Investors should watch for the execution of definitive agreements and any updates on launch-readiness milestones as indicators of commercial momentum.
Bottom Line?
Securing Strive Pharmacy's exclusive fulfilment rights is a pivotal step that materially de-risks LTR Pharma's US launch of ROXUS, but final agreements and operational readiness remain key hurdles ahead.
Questions in the middle?
- Will LTR Pharma finalise definitive agreements with Strive Pharmacy within the stipulated timeframe?
- How effectively will the multi-channel distribution strategy convert into patient uptake in the competitive US ED market?
- What regulatory or operational challenges might arise in scaling ROXUS via the 503A personalised medicine pathway?